Health Care & Life Sciences » Pharmaceuticals | Kaken Pharmaceutical Co. Ltd.

Kaken Pharmaceutical Co. Ltd. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
15,496
18,611
35,292
31,092
27,686
24,922
Depreciation, Depletion & Amortization
2,538
2,400
2,242
1,937
2,124
2,599
Other Funds
6,303
2,103
6,687
13,976
6,915
9,022
Funds from Operations
11,731
18,908
30,847
19,051
22,894
18,499
Changes in Working Capital
1,932
4,171
3,782
3,724
1,191
2,630
Net Operating Cash Flow
13,663
14,737
27,065
15,327
21,703
21,129
Capital Expenditures
2,126
2,028
3,217
2,354
1,888
Sale of Fixed Assets & Businesses
-
1,941
-
-
-
Purchase/Sale of Investments
3
3
753
1,019
1,252
Net Investing Cash Flow
2,135
473
4,105
3,503
3,245
Cash Dividends Paid - Total
3,936
4,263
5,463
6,288
6,085
Issuance/Reduction of Debt, Net
4,196
-
320
-
-
Net Financing Cash Flow
10,992
7,900
5,984
9,800
9,530
Net Change in Cash
536
7,310
16,976
2,024
8,928
Free Cash Flow
11,592
12,783
23,941
13,161
20,014
Other Sources
-
563
-
-
-
Change in Capital Stock
2,860
3,637
201
3,512
3,445
Other Uses
6
-
135
130
104

About Kaken Pharmaceutical Co.

View Profile
Address
2-28-8 Honkomagome
Tokyo Tokyo 113
Japan
Employees -
Website http://www.kaken.co.jp
Updated 07/08/2019
Kaken Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products, medical devices, agrochemicals, and animal health products in Japan. Its operations are carried out through the following business divisions: Pharmaceuticals and Medical Devices, Agrochemicals and Animal Health Products, Overseas Activity, Research & Development, and Licensing Opportunities. The Pharmaceuticals and Medical Devices division offers artz(anti-osteoarthritis), clenafin (topical onychomycosis treatment product), seprafilm (anti-adhesive absorbent barrier), lipidil (anti-hyperlipidemia product), fiblast spray (wound-healing product), mentax (anti-trichophyton product) and generic drugs.